Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.586 USD | -3.46% | +2.81% | -92.34% |
05-21 | FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD | CI |
05-08 | Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-92.34% | 4.19M | |
+38.36% | 52.5B | |
+36.73% | 39.31B | |
-8.63% | 39.01B | |
+25.46% | 28.2B | |
-11.17% | 26.57B | |
+11.44% | 26.2B | |
+45.09% | 14.15B | |
+32.93% | 12.62B | |
-5.30% | 11.74B |
- Stock Market
- Equities
- CING Stock
- News Cingulate Inc.
- HC Wainwright Adjusts Price Target on Cingulate to $8 From $3.50, Maintains Buy Rating